Alexandria Real Estate Equities, the US-based life sciences real estate investment trust, has completed delivery of a 427,000 square foot research and development facility for pharmaceutical giant Bristol Myers Squibb. The facility, located in the UK, is purpose-built to support drug discovery and early-stage clinical research, reinforcing the country's position as a global hub for life sciences innovation.
The transaction highlights the growing demand for specialised laboratory and R&D space in the UK, particularly in the ‘golden triangle’ of Oxford, Cambridge, and London. Bristol Myers Squibb, which has a significant UK presence, will use the site to advance its pipeline of therapies across oncology, immunology, and cardiovascular disease.
Alexandria has been a major investor in UK life sciences real estate, with a portfolio that includes the Cambridge Biomedical Campus and other key innovation districts. The company’s latest delivery comes amid a broader push by the UK government to attract pharmaceutical investment, including tax incentives and streamlined planning for lab developments.
For UK investors, the deal signals confidence in the long-term outlook for the life sciences property market, which has outperformed broader commercial real estate in recent years. However, analysts caution that rising construction costs and interest rates could temper future development. 'The sector remains robust, but developers are increasingly selective about new projects,' said a property analyst at a London-based research firm.
The facility is expected to create hundreds of high-skilled jobs, including roles for scientists, technicians, and support staff. Local economic development agencies have welcomed the investment, which bolsters the UK's ambition to become a ‘science superpower’ by 2030.